SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Sage Therapeutics, Inc. Investors.

NEW YORK, May 16, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE). Such investors are advised to get in touch Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The subject matter of the investigation is whether Sage and certain of its officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information about joining the class action lawsuit)

At April 17, 2024, Sage issued a press release stating: “…topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral drug Dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) . in Parkinson’s disease (PD).” Sage stated that “the PRECEDENT study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with dalzanemdor once daily compared to placebo has”.

On this news, Sage’s share price fell $3.06 per share or 19.58% to close $12.57 per share April 17, 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel Aviv, is considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the deceased Abraham L. PomerantzPomerantz, known as the dean of the class action bar, pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of securities victims Fraud, breaches of fiduciary duty and corporate misconduct. The company has recovered billions of dollars in damages on behalf of the class plaintiffs. See www.pomlaw.com.

Lawyer advertising. Previous results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 ext 7980

SOURCE Pomerantz LLP